Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Marburg and Lassa, Malaria and Zika virus. We have also initiated programs to develop a multi-antigen vaccine to treat chronic Hepatitis B (HBV) infections, a vaccine to treat human papilloma virus (HPV)-induced cancers and a vaccine against tumor associated antigen MUC1 that is associated with metastic progression of many cancer types including breast, ovarian, gastric, liver, pancreas, renal and  lymph nodes.